SEC Form 4 · accession 0001179110-15-000425
GILEAD SCIENCES, INC. · GILD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard James Whitley
Director
Period of report
Jan 2, 2015
Accepted (ET)
Jan 6, 2015 · 2:12 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882095
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 2, 2015 | M | 5,000 | $26.99 | A | 20,641 | D | |
| Common StockF3 | Jan 2, 2015 | S | 4,000 | $95.0359 | D | 16,641 | D | |
| Common StockF4 | Jan 2, 2015 | S | 1,000 | $95.956 | D | 15,641 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (Right to Buy)F2 | $26.99 | Jan 2, 2015 | M | 5,000 | D | — | Jul 30, 2018 | Common Stock | 5,000 | 10,000 | D |
Explanation of responses
- F1The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
- F2Options are 50% vested on the first anniversary of the date of grant and 100% vested on the second anniversary of the date of grant.
- F3Sale prices reported for the transactions reported here range from $94.61 to $95.49. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- F4Sale prices reported for the transactions reported here range from $95.61 to $96.29. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.